Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.010
Neutral
RSI(14)
52.588
Neutral
STOCH(KDJ)(9,3,3)
36.479
Neutral
ATR(14)
0.431
High Vlolatility
CCI(14)
4.658
Neutral
Williams %R
66.185
Sell
TRIX(12,20)
0.453
Sell
StochRSI(14)
0.000
Sell
Search
Profound Medical Corp
PROFAdd to Watchlist
6.970USD
-0.230-3.19%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
251.34MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Profound Medical Corp
Currency: USD Updated: 2026-05-15Key Insights
Profound Medical Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 84 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.05.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Profound Medical Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Profound Medical Corp Highlights
StrengthsRisks
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 123.61% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 16.10M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 16.10M.
Fairly Valued
The company’s latest PE is -5.60, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 17.27M shares, increasing 8.83% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.15.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
11.050
Target Price
+53.47%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Profound Medical Corp is 7.42, ranking 73 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 5.34M, representing a year-over-year increase of 103.62%, while its net profit experienced a year-over-year increase of 34.23%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.48
Operational Efficiency
2.91
Growth Potential
9.32
Shareholder Returns
7.41
Profound Medical Corp's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Profound Medical Corp is 7.49, ranking 79 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -5.60, which is -52.38% below the recent high of -2.66 and -103.14% above the recent low of -11.37.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 84/206
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Profound Medical Corp is 8.80, ranking 15 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 11.12, with a high of 12.00 and a low of 11.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
11.050
Target Price
+58.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
93
Total
4
Median
7
Average
Company name
Ratings
Analysts
Profound Medical Corp
PROF
5
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Profound Medical Corp is 6.64, ranking 108 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 7.74 and the support level at 6.35, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
7.132
Sell
MA10
7.086
Sell
MA20
6.952
Buy
MA50
6.344
Buy
MA100
6.896
Buy
MA200
6.266
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Investments Canada ULC
Gagnon Securities LLC
Rosalind Advisors, Inc.
Timelo Investment Management Inc.
Gagnon Advisors, LLC
Letko, Brosseau & Associates Inc.
Alyeska Investment Group, L.P.
Menawat (Arun Swarup Ph.D.)
1
2
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Profound Medical Corp is 3.00, ranking 132 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.52
VaR
+6.11%
240-Day Maximum Drawdown
+43.00%
240-Day Volatility
+78.24%
Return
Best Daily Return
60 days
+13.01%
120 days
+13.01%
5 years
+29.04%
Worst Daily Return
60 days
-29.11%
120 days
-29.11%
5 years
-29.11%
Sharpe Ratio
60 days
+0.44
120 days
+0.78
5 years
+0.14
Risk Assessment
Maximum Drawdown
240 days
+43.00%
3 years
+70.84%
5 years
+81.88%
Return-to-Drawdown Ratio
240 days
+0.63
3 years
-0.22
5 years
-0.12
Skewness
240 days
-0.77
3 years
-0.04
5 years
+0.45
Volatility
Realised Volatility
240 days
+78.24%
5 years
+71.90%
Standardised True Range
240 days
+6.09%
5 years
+7.49%
Downside Risk-Adjusted Return
120 days
+94.71%
240 days
+94.71%
Maximum Daily Upside Volatility
60 days
+65.27%
Maximum Daily Downside Volatility
60 days
+67.48%
Liquidity
Average Turnover Rate
60 days
+0.65%
120 days
+0.63%
5 years
--
Turnover Deviation
20 days
-16.14%
60 days
+84.56%
120 days
+78.45%
Peer Comparison
Healthcare Equipment & Supplies
Profound Medical Corp
PROF
6.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bruker Corp
BRKR
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
